Skip to content

Clinical trial of Beach Body Gummies (BBG) in weight management.

Clinical validation of safety and efficacy of Beach Body Gummies (BBG) in weight management. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052235
Enrollment
60
Registered
2023-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Beach Body Gummies: 1 gummy twice a day after breakfast and dinner along with lifestyle modification (diet and exercise) for 90 days Control Intervention1: Lifestyle modification (diet

Sponsors

Aesthetic Nutrition Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Obese patients (male/female and aged between 20-45 yrs. both inclusive); 2. BMI between 30 - 40 kg/m2; 3. Subjects with or without comorbidities, if comorbidity exists should be on stable prescription and with following criteria- hypertension (Less than or equal to 140/90 mmHg on prescription), type 2 DM (HbA1C Less than or equal to 7.5 on prescription); 4. Willing to provide consent; 5. Willing for follow up

Exclusion criteria

Exclusion criteria: 1. Subjects with any acute illness requiring immediate medical care; 2. Subjects with type I DM/complicated cardiovascular diseases / HbA1C more than 7.5. / history of TIA, cerebrovascular accident, stroke or any revascularization; 3. Known subjects of hepatic/renal failure; 4. Pregnant, breast feeding or planning to become pregnant during the study; 5. Any other condition which proves subject unfit for the study participation.

Design outcomes

Primary

MeasureTime frame
1. Changes in body weight from screening to end of the study. 2. Changes in BMI from screening to end of the study. 3. Changes in anthropometric parameters such as waist & hip circumference and body fat %, visceral fat % by bioelectrical impedance analysis (BIA) at screening and end of the study.Timepoint: Screening Day ,Baseline Day, Day 30(visit 1), Day 60(visit 2), Day 90(visit 3)

Secondary

MeasureTime frame
1. Changes in quality of life of subjects by modified IWQOL-Lite score at screening and end of the study. 2. Changes in insulin resistance calculated as HOMA-IR score at screening and end of the study. 3. Changes in lipid profile at screening and end of the study. 4. Changes in general complaints like profuse sweating, irregular thirst, dyspnea and uncontrolled hunger on 0-10 VAS score from screening to end of the study.Timepoint: Screening Day ,Baseline Day, Day 30(visit 1), Day 60(visit 2), Day 90(visit 3)

Countries

India

Contacts

Public ContactMs Ekta Pathania

Aesthetic Nutrition Pvt. Ltd.

prachi.a@powergummies.com8588930646

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026